Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

     

News

Anatara Lifesciences Limited's (ASX:ANR) Antibiotic Alternative Edges Closer to Commercialisation as UN Declares Drug Resistance 'The Greatest and Most Urgent global risk'

🕔10/4/2016 8:30:00 AM 1535

Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) APVMA Submission Major Milestone Achieved

🕔10/4/2016 8:29:45 AM 1992

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has lodged its application for approval to register Detach(TM) with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach(TM) is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful Completion of Target Safety Study

🕔9/8/2016 8:27:28 AM 2214

Anatara Lifesciences (ASX:ANR) is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for DetachTM, the Company's lead product for the control of diarrhoea in piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4E and Financial Report

🕔8/30/2016 8:20:29 AM 1672

Anatara Lifesciences Ltd (ASX:ANR) today released its Appendix 4E for the period ending 30th June 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4C - Quarterly

🕔7/22/2016 8:47:40 AM 1589

Chairman & CEO, Dr Mel Bridges said, "We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch," Dr Bridges added.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation and Update

🕔7/11/2016 9:49:57 AM 1936

Anatara Lifesciences (ASX:ANR) releases its latest institutional roadshow presentation and market update. This week CEO & Chairman Dr Mel Bridges and Co-Founder and Chief Scientific Officer (CSO) Dr Tracey Mynott will be conducting a roadshow updating existing and potential new institutional investors and analysts.

Read Full Article

FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Executive Interview Series with Chief Scientific Officer Dr. Tracy Mynott

🕔6/30/2016 2:32:40 PM 5817

Anatara Lifesciences Limited (ASX:ANR) Chief Scientific Officer, Dr. Tracy Mynott, speaks with Tom Piotrowski at CommSec's The Executive Series, by Commonwealth Bank Australia (ASX:CBA).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Expands Executive Team

🕔6/27/2016 10:25:33 AM 2448

Anatara Lifesciences (ASX:ANR) announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation - Natural Alternative to Antibiotics

🕔6/23/2016 11:12:54 AM 2099

Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges presented at the Finance News Network CEO Conference and the Gold Coast Investment Showcase this week.

Read Full Article

Biotech Investors Move Ahead on the Learning Curve

🕔6/11/2015 3:13:43 PM 5202

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Read Full Article
###

4,933 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 122) (Last 30 Days: 379) (Since Published: 4933) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Social Media